Vistagen Therapeutics Stock Z Score
| VTGN Stock | USD 4.72 0.11 2.28% |
VistaGen | Z Score |
VistaGen Therapeutics Company Z Score Analysis
VistaGen Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
VistaGen Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for VistaGen Therapeutics is extremely important. It helps to project a fair market value of VistaGen Stock properly, considering its historical fundamentals such as Z Score. Since VistaGen Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VistaGen Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VistaGen Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
As per the company's disclosures, VistaGen Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
VistaGen Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VistaGen Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics of similar companies.VistaGen Therapeutics is currently under evaluation in z score category among related companies.
VistaGen Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in VistaGen Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of VistaGen Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing VistaGen Therapeutics' value.| Shares | Two Sigma Investments Llc | 2023-12-31 | 192.1 K | Bml Capital Management Llc | 2023-12-31 | 150 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 138.5 K | Bank Of Montreal | 2023-12-31 | 96.9 K | Bmo Capital Markets Corp. | 2023-12-31 | 96.9 K | Blair William & Co | 2023-12-31 | 88 K | Citigroup Inc | 2023-12-31 | 58.4 K | Advisorshares Investments, Llc | 2023-12-31 | 54.3 K | State Street Corporation | 2023-12-31 | 49.5 K | Nantahala Capital Management, Llc | 2023-12-31 | 3.6 M | Great Point Partners Llc | 2023-12-31 | 1.9 M |
VistaGen Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (19.16) % | ||||
| Current Valuation | 6.23 M | ||||
| Shares Outstanding | 27.03 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 63.23 % | ||||
| Number Of Shares Shorted | 1.28 M | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 126.79 X | ||||
| Revenue | (227.3 K) | ||||
| Gross Profit | (227.3 K) | ||||
| EBITDA | (58.74 M) | ||||
| Net Income | (59.25 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 2.72 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.56 X | ||||
| Cash Flow From Operations | (49.72 M) | ||||
| Short Ratio | 4.34 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.81 | ||||
| Market Capitalization | 129.45 M | ||||
| Total Asset | 21.09 M | ||||
| Retained Earnings | (326.85 M) | ||||
| Working Capital | 12.94 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
| Net Asset | 21.09 M |
About VistaGen Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VistaGen Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VistaGen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VistaGen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:Check out VistaGen Therapeutics Piotroski F Score and VistaGen Therapeutics Valuation analysis. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for VistaGen Stock analysis
When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.077 | Quarterly Revenue Growth 1.291 | Return On Assets (0.26) | Return On Equity (0.45) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.